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We have recently reported (1) the isolation of a cDNA sequence coding for
human IL-4 B cell stimulatory factor 1 (BSF,) .' This lymphokine is a T cell-
derived glycoprotein consisting of 129 amino acids with two potential N-glyco-
sylation sites . Human IL-4 is able to induce the proliferation of activated B
lymphocytes (Defrance, T ., B . Vanbervliet, J . P . Aubry, et al ., manuscript
submitted for publication) and activated T lymphocytes (Spits, H ., H . Yssel, Y .
Takebe, et al . manuscript submitted for publication) . During the course of our
studies aimed at characterizing the phenotype of the B lymphocyte population
proliferating in response to IL-4, we studied the expression of several activation
markers . The most striking phenotypic modification mediated by IL-4 was the
induction on B lymphocytes of the low-affinity receptor (RL) for IgE
(FcERL/CD23) (2, 3), as determined by the binding of the FcERL/CD23-specific
mAb 25 . We also show in this report that IFN-7 specifically inhibits the IL-4-
mediated induction of FcERL/CD23 .
Materials and Methods
Reagents. Insolubilized rabbit anti-human IgM (Bio-Rad Laboratories, Richmond,
CA) was used at the final concentration of 5 ag/ml . The anti FcERL (CD23 antigen)-
specific mAb 25 was produced after immunizing mice with RPMI 8866 cells (2) . The
FITC-conjugated goat anti-mouse Ig used in the indirect immunofluorescence assays was
purchased from Grub (Vienna, Austria) . OKT mAbs were from Ortho Diagnostic Systems
Inc . (Westwood, MA) ; Leu mAbs were from Becton Dickinson Monoclonal Center
(Mountain View, CA) ; B1, M02, and MO1 were from Coulter Immunology (Hialeah,
FL) .
Escherichia coli-derived rIFN-y (10' IU/mg) was obtained from Schering Research,
Bloomfield, NJ . IL-4 was obtained as supernatants from COS-7 cells transfected with pcD
vector containing the human IL-4 cDNA clone (1) . 1 U of IL-4 is defined as the amount
providing a half-maximal [sH]TdR uptake in activated PHA blasts (1) . Some experiments
were performed with purified IL-4 . Mock preparations consisting of culture supernatants
of COS-7 cells transfected with a nonrelated cDNA were also used . Human rIL-2 was
`Abbreviations used in this paper:
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AET, aminoethylisothiouronium bromide ;BCGF,B cell growth
factor; BSF,, B cell stimulatory factor 1; cBCGF, commercial BCGF ; EBV LCL, EBV-transformed
lymphoblastoid cell lines ; FcERL, low-affinity receptor for IgE on lymphoid cells . FLS, forward light
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obtained as E. coli lysates from Dr. R. Kastelein at DNAX and as a purified protein from
Amgen Biologicals (Thousand Oaks, CA). Human rIL-1a wasobtained from Dr. Zurawski
at DNAX in the form of E. coli lysates. It was purified by SDS-PAGE and the IL-1 was
eluted from its migration area in the gel by reverse electrophoresis. A commercial
preparation of a low-molecular-weight B cell growth factor (BCGF) purified from the
culture supernatants of PHA-stimulated PBL was obtained from Cellular Products Inc.
(Buffalo, NY) and is referred to in the text as commercial BCGF (cBCGF). This prepara-
tion was free from IL-2 and IFN-y activity, as determined by measurement of the [sH]-
TdR uptake by the IL-2-dependent mouse T cell line CTLL-2 and an ELISA assay,
respectively.
B Cell Preparations and Cultures.
￿
B cells were isolated either from tonsils or from
blood cytapheresis residues. Mononuclear cells were separated by the standard Fi-
coll/Hypaque gradient method. Tonsil Bcellswere obtained by twicerosetting with amino
ethyl isothiouronium bromide (AET)-treated SRBC, while blood B cells were submitted
to a single rosetting with AET-treated SRBC followed by complement-mediated lysis of
the remaining T cells with the use of anti-T3 (CD3), -T4 (CD4), -T8 (CD8), -TI 1 (CD2)
mAbs. Depletion of blood monocytes, null cells and large granular lymphocytes was
achieved by L-leucinemethyl ester treatmentaccordingto themethod described by Thiele
et al. (4). The B cell-enriched populations obtained were typically >95% surface Ig-
positive, >95% B1 antigen (CD20)-positive. <1% of the cells were positively stained by
the T cell markers Leu-1, OKT4, OKT8, and OKT1 I or by the monocyte markers: Leu-
M3, MOI (CD11), M02 (CD14). <1% ofthecells reacted with the NK cell markers: Leu-
7 and Leu-11 (CD16).
Purified B cells were cultured at 106 cells/ml in Iscove's medium enriched with 50
gg/ml human transferrin, 5 tag/ml bovine insulin, 0.5% BSA, oleic, linoleic, and palmitic
acids (all from Sigma Chemical Co., St. Louis, MO) as described by Yssei et al. (5). 2%
FCS was added to the medium.
Analysis with a FACS.
￿
Fluorescence analysis was performed with a FACS 440 (Becton
Dickinson & Co., Sunnyvale, CA) equipped with a 5 W argon laser running at 488 nm,
0.5 W. Fluorescence parameters were collected usinga built in logarithmic amplifier after
gating on the combination of forward light scatter (FLS) and perpendicular light scatter
(PLS), which was used to discriminate viable from nonviable cells.
Cell Staining.
￿
4 x 105 cells were incubated with 50 Al of the appropriately diluted
mAb in 0.2-ml microtiter plate wells. After two washes with PBS containing 1% BSA,
0.01% sodium azide, cells were incubated with fluoresceinated F(ab')2 fragments of goat
anti-mouse Ig (Grub) for 30 min at 4°C. After three washes with PBS/BSA/azide, the
cells were analyzed with the FACS.
Simultaneous Measurement ofRNA Content and Surface Antigen Expression.
￿
The proce-
dure used was adapted from Shapiro (6). 106 cells/mI in PBS/1% BSA/0.01% sodium
azide were incubated at 37°C for 45 min with 5 AM pyronin Y (PY; Aldrich Chemical
Co., Milwaukee, WI). After centrifugation the cells were resuspended in cold PBS/BSA
containing 4,uM PY (PBS/PY) and the mAb was addedat the appropriate dilution. After
an incubation of 30 min at 4°C the cells were washed twice in cold PBS/PY then
resuspended in PBS/PY containing the fluorescent-conjugated goat anti-mouse Ig. After
30 minat VC, C, the cells were washed twice with cold PBS/PY and resuspendedin PBS/PY.
Analyses were performed within 15 min after staining. 15,000 cells were recorded. The
green fluorescence (530 nm) specific for antibody staining is recorded with logarithmic
amplification; the red fluorescence (>600 nm) specific for RNA staining is recorded with
linear amplification.
Results
IL-4 Specifically Induces the Expression ofFcE Receptors/CD23 on Normal Human
B Cells. Highly purified tonsil B lymphocytes not stimulated or stimulated by
insolubilized anti-IgM antibody were cultured with or without IL-4 (80 U/ml of
a COS-7 cells transfection supernatant). After 24 or 48 h, cells were stained with102
100
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FIGURE 1 . IL-4 induces the
expression of FccRL/CD23
on purified tonsil B cells.
FceRL/CD23 is detected by
immunofluorescence flow cy-
tometry withmAb25, an anti-
FCeRL/CD23 mAb . Purified
tonsil B cells were cultured for
24 h (A and B) or 48 h (C and
D) without (A and C) or with
(B and D) IL-4, without or
with insolubilized anti-IgM an-
tibody (5 ug/ml) . The IL-4
was a COS-7 transfection su-
pernatant used at 80 U/ml .
FIGURE 2 .
￿
Highly purified IL-4 obtained
from COS-7 transfection supernatants is
able to induce FceRL/CD23 on purified ton-
sil B cells. Purified tonsil B lymphocytes
were cultured for 48 h with insolubilized
anti-IgM antibodies and increasing concen-
trations of IL-4. The number of cells ex-
pressing FceRL/CD23 was estimated by im-
munofluorescence flow cytometry after
staining withmAb 25 .
mAb 25, which is specific for the FceRL/CD23. FACS histograms (Fig. 1) show
that IL-4 is able to induce the expression ofFceRL/CD23 on nonactivated B cells
but that the concomitant activation with anti-IgM antibodies increases the num-
ber of cells expressing FceRL/CD23 as well as the intensity of FceRL/CD23
expression on these cells. The nonactivated and the anti-IgM-activated B lym-
phocytes cultured with a mock COS-7 transfection supernatant did not signifi-
cantly express FceRL/CD23. The IL-4-induced expression of FceRL/CD23 was
confirmed by the binding of soluble IgE as assessed by flow cytometry after
successive incubations of the cells with soluble IgE, an anti-IgE-specific mAb,
and a FITC-labeled goat anti-mouse Ig conjugate (data not shown) .
To determine the concentration that induces optimal FceRL/CD23 induction,
experiments were carried out with highly purified rIL-4 obtained from trans-
fected COS-7 supernatants. Data in Fig . 2 show that the maximum expression
of FceRL/CD23 on anti-IgM-activated B cells is obtained with 700 pg/ml IL-4 .
The half-maximal induction of FceRL/CD23 is obtained with -176 pg/ml IL-4 .
It has been shown that activated B lymphocytes can proliferate in response to1462 INTERLEUKIN 4 INDUCES Fce RECEPTORS ON B CELLS
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FcER L+ Cells *
Anti-IgM
activated
* Purified tonsil B cells were cultured for 48 h with the different cytokines
and the FcfRL/CD23 expression was assessed by flow cytometry using
mAb 25 .
Supernatants from EBV-transformed cell lines containing BCGF activity
as determined on anti-IgM-preactivated B cells but no IL-4, as deter-
mined by Northern analysis of isolated mRNA .
4 Supernatant from an allogeneic IL-2-dependent T cell clone stimulated
by its specific alloantigen and containing IL-2, IFN- -y, andBCGF activ-
ities .
many different lymphokines : IL-4 (Defrance, T ., B . Vanbervliet, J . B . Aubrey,
et al ., manuscript submitted for publication), a low-molecular-weight BCGF (7),
a high-molecular-weight BCGF (8), B cell-derived BCGFs (9, 10), IL-2 (11), IL-
1 (12, 13), and IFN-y (14, 15) . However, IL-2, IL-la, IFN-y, a low-molecular-
weight BCGF (cBCGF as obtained from Cellular Products Inc.), B cell-derived
BCGF (as obtained from EBV-transformed B cell line supernatants), and aT cell
clone supernatant (containing IL-2, IFN-y, and BCGF) were unable to induce
FcERL/CD23 expression (Table I) . cBCGF that cooperates with IL-4 for the
proliferation of activated B lymphocytes (Defrance, T ., B . Vanbervliet, J . B .
Aubrey, et al ., manuscript submitted for publication) does not alter the induction
of FcERL/CD23 on B cells (data not shown) . The induction of FccRL/CD23 on
normal B cells by IL-4 therefore seems to be a specific property of this lympho-
kine .
IFN-y Inhibits the IL-4-induced FccRL/CD23 Expression. Since we failed to
demonstrate the presence ofFccRL/CD23-inducing activity in many T cell clone
supernatants, including clone 2F1 from which the IL-4 cDNA was isolated, we
investigated whether these T cell clone supernatants would contain factors
inhibiting the IL-4-induced FcERL/CD23 expression on normal B lymphocytes .
Recombinant lymphokines (IL-1, IL-2, IFN-y) were assayed for their potential
inhibitory action on the IL-4-induced Fc(RL/CD23 on B cells . The supernatant
of clone 2F1 was found to strongly inhibit the IL-4-induced expression of
FCER j ./CD23 (data not shown) . Among the three recombinant lymphokines
0 1±1 3±2
Mock COS-7 (I%) 1±I 1±1
IL-4 (80 U/ml) 20±2 48±4
IL-la (10 IU/ml) 1±1 2±1
IL-2 (20 IU/ml) 2±1 1±1
IFN- -y (50 U/ml) 2±1 2±1
IFN-1' (1,000 U/ml) 4±1 1±1
cBCGF (20%) 1±1 1±1
UD 58 supernatant (5%)$ 2±1 1 1
RPMI 8866 supernatant (20%)* 3±2 3±1
HG 120 supernatant (10%)¢ 2±1 1±1DEFRANCE ET AL .
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tested, IFN-y was found to be a very potent inhibitor of the IL-4-induced
FceRL/CD23 expression, while neither IL-1 nor IL-2, nor cBCGF affected the
induction of the FceRL/CD23 (data not shown) . Data in Fig . 3 show that
concentrations of IFN-y as low as 1 U/ml can partially inhibit the FceRL/CD23
induction . Inhibition of IL-4-induced FceRL/CD23 expression by IFN-y was
observed after 24 h of culture, but optimal inhibition was obtained after a 48-h
incubation period . At optimal concentrations of IL-4, IFN-y did not totally block
the induction of FceRL/CD23, while a complete inhibition of FceRL/CD23
induction could be obtained with IFN-y when suboptimal concentrations of IL-
4 were used (data not shown) . These data demonstrate that IFN-'Y strongly
antagonizes IL-4-induced FceRL/CD23 expression on B cells .
IL-4 Induces the Expression of FceRL/CD23 on B Cells in the Go Phase of the
Cycle. Although IL-4 induces FceRL/CD23 on tonsil B cells without preactiva-
tion, it has to be taken into account that the B cells studied here were obtained
from donors with tonsillitis . This implies that a significant proportion of the B
cells used were preactivated in vivo . To determine whether IL-4 induced
FceR 1./CD23 on nonpreactivated B cells, the RNA content of the cellsexpressing
FceRL/CD23 was measured simultaneously . IL-4 alone (Fig . 4A) or in combina-
tion with insolubilized anti-IgM antibody (Fig . 4B) induced FceRL/CD23 on a
fraction of nonactivated B cells with low RNA contents but on an activated B
cell fraction with relatively high RNA contents . The notion that preactivation of
the B cells is not required for the induction of FceRL/CD23 by IL-4 is also
supported by the finding that IL-4 induced a strong expression of FceRL/CD23
on peripheral blood B cells that are in the Go phase of the cell cycle, as well as
on high-density tonsillar B cells obtained after Percoll-gradient centrifugation
(data not shown) .
Taken together these data strongly suggest that resting B cells express func-
tional IL-4 receptors and demonstrate that not all the activated B cells express
FcER 1,/CD23 upon culture with IL-4 .
Discussion
In the present study we have demonstrated that human rIL-4 (BSF I) (1) is able
to induce the expression of FceRL/CD23 on human B lymphocytes . This has
been demonstrated using the binding of the FceRL/CD23 mAb 25 (2) or the
binding of soluble IgE (data not shown) . Concomitant B cell activation by1464
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FIGURE 4 . IL-4 induces FcERL/CD23 on B
cells in theG o phase of the cycle . Purified tonsil
B cells were cultured for 24 h with IL-4 (A) or
IL-4 and anti-IgM antibody (B). Cells were
stained with biotinylated mAb 25/FITC-con-
jugated avidin (green fluorescence, ordinate,
log scale) and PY (red fluorescence, abscissa,
linear scale) and were analyzed by double-flu-
orescence flow cytometry as described under
Materials and Methods . The IL-4 was a COS-7
transfection supernatant used at 80 U/ml .
insolubilized anti-IgM antibody resulted in enhanced FcfRL/CD23 induction by
IL-4, suggesting an increased expression of IL-4 receptors on B cells . The finding
that activation of the B cells enhanced IL-4-mediated FcERL/CD23 induction
suggested that IL-4 alone was inducing FcERL/CD23 on the in vivo-preactivated
B cells that are known to represent a significant proportion of tonsillar B
lymphocytes . This however turned out not to be the case since double-fluores-
cence analysis carried out with mAb 25 and PY demonstrated that IL-4 induced
FcERL/CD23 on B cells containing low levels ofRNA (a characteristic of cells in
the Go phase of the cycle) and on B cells with increased levels ofRNA (G I phase
of the cycle) .
The induction of FcERL/CD23 on B cells seems to be specific for IL-4 . rIL-2,
rIFN-y, rIL-1a, semipurified low-molecular-weight BCGF or the supernatant of
EBV lymphoblastoid cell lines (LCL) containing BCGF activity but no IL-4 (asDEFRANCE ET AL .
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determined by the absence of IL-4 mRNA in the cell line) were unable to induce
FceRL/CD23 expression on normal B cells. Human rIL-4 has a FceRL/CD23-
inducing activity comparable to the lymphokine purified from PHA-activated
mononuclear cells supernatants studied by Suemura et al . (16) . None of the
tested lymphokines acted in concert or in synergy with IL-4, but interestingly,
IFN-y strongly inhibited the FceRL/CD23-inducing effect of IL-4 . Strong inhib-
itory effects were observed at IFN-y concentrations of 1 IU/ml. Although
considerable blocking effects were obtained after 24 h of incubation with IL-4,
the effect was most pronounced after 48 h. The mechanism by which IFN-y
blocks IL-4-induced FceRL/CD23 expression is presently under investigation.
This inhibitory effect ofIFN-y is in line with the described antagonizing effects
of marine IFN-y on the proliferation of anti-IgM-activated B cells (17), the
increase of class lI MHC antigens on B cells, the increase in cell size (18, 19),
and IgE and IgGI production by LPS blasts (20) induced by IL-4 . By contrast,
the IL-4-induced proliferation of preactivated human B cells was stimulated by
IFN-y (Defrance, T., B. Vanbervliet, J. P. Aubrey, et al ., manuscript submitted
for publication) .
At the present time the biological significance ofthe IL-4-induced FceRL/CD23
expression is unclear. The recent suggestion by Gordon et al . (21, 22) that the
CD23 antigen may be the receptor for the low-molecular-weight BCGF (7) is
worth considering, since it is in line with our data that indicate that IL-4
synergizes with the low-molecular-weight BCGF in inducing the proliferation of
preactivated Bcells (Defrance,T.,B. Vanbervliet, J. P. Aubrey, et al ., manuscript
submitted for publication). The demonstration that IL-4 is able to induce (a)
FceRL on human B lymphocytes, (b) the proliferation of marine mast cells, and
(c) IgE production by murine LPS blasts, demonstrates that IL-4 plays a major
role in the IgE system at both the regulatory and the effector levels since it has
been suggested that FceRL+ B cells play a major role in the regulation of IgE
secretion (23) . This hypothesis is confirmed by the recent finding that the in
vivo injection of a mAb specific for mouse IL-4 (24) into Nippostrongylus brasi-
liensis-infected mice abrogates the induction of IgE production mediated by this
treatment (25) . The biological functions of FceRL/CD23 on B lymphocytes and
the biological significance of its modulation by IL-4 and IFN-y remain to be
determined .
Summary
Human rIL-4 is able to induce the expression of low-affinity receptors for IgE
(FceRL/CD23) on resting B lymphocytes, as determined by the binding of either
the anti FceRL/CD23-specific mAb 25 or IgE. Stimulation of B cells with
insolubilized anti-IgM antibody increases the number of cells expressing
FceRL/CD23 upon culturing with IL-4 and enhances the level of FceRL/CD23
expression on these cells. FceRL/CD23 induction is specific for IL-4 since IL-la,
IL-2, IFN-y, B cell-derived B cell growth factor (BCGF), and a low-molecular-
weight BCGF were ineffective . IFN-y strongly inhibited the induction of
FceRL/CD23 by IL-4 .
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